The Healthcare sector is made up of devices and systems that support healthcare organizations such as hospitals, doctor’s offices, surgical centers, and more. Healthcare technologies range from equipment like imaging machinery and robotic surgical assistants to patient recordkeeping applications and scheduling support. Register today to discover how Forge can help you buy and sell private shares.
Register to add companies to your watchlist and get access to bids/asks activity, last matched price and trade eligibility details.
Register| Active Market | Forge Price1 | Last Funding Round | Trade Eligibility | ||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Company | Sector & Subsector | Market Activity4 |
Highest Bid | Lowest Ask | Last Matched | +/- to LFR | $ Total Bids |
$ Total Asks |
# Bids |
# Asks |
Current Price |
6-month |
1-year |
Total Funding |
Round | Date | Amount Raised |
Post-Money Valuation3 |
Price |
Key Investors | Common | Preferred | Fund | ||
| Neuralink | Healthcare Medical Devices | Medium | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $1.34B | Series E | 6/2/2025 | $650M | $9.65B | $49.09 | -- | |||||
| Scribe Therapeutics | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $120.71M | Series B | 3/31/2021 | $100M | $300.81M | $6.05 | Avoro Ventures, Avoro Capital Advisors, OrbiMed, Andreessen Horowitz, Perceptive Advisors, T. Rowe Price, Wellington Management, RA Capital Management, Menlo Venture | |||||
| Life Biosciences | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | $400.80K | -- | 2 | -- | Not available | -- | -- | -- | Not available | -- | -- | -- | -- | -- | |||||
| OURA | Healthcare Digital Health | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $1.28B | Not available | -- | -- | -- | -- | -- | |||||
| Abridge | Healthcare Healthcare Software | Low | $xx.xx | $xx.xx | $xx.xx | xx% | $100.02K | -- | 1 | -- | $170.20 | -9.95% | +7.40% | $773.91M | Series E | 6/24/2025 | $315.93M | $5.3B | $158.48 | Andreessen Horowitz, Khosla Ventures, Archerman Capital, California Health Care Foundation, Catalio Capital Management, Eli Lilly, Emerson Collective, Harper Ventures, Soma Capital, WndrCo | |||||
| Altos Labs | Healthcare Biotech & Pharma | Low | $xx.xx | $xx.xx | $xx.xx | xx% | -- | $200.01K | -- | 2 | Not available | -- | -- | $11.13B | Series C | 2/14/2024 | $1.5B | $6.33B | $25.02 | Undisclosed Investors | |||||
| Colossal Biosciences | Healthcare Biotech & Pharma | Low | $xx.xx | $xx.xx | $xx.xx | xx% | $360.00K | $450.00K | 1 | 1 | Not available | -- | -- | $620.64M | Series C | 2/3/2026 | $380M | $10.32B | $24.89 | TWG Global, Peter Jackson, US Innovative Technology Fund, Robert Nelsen, United Arab Emirates | |||||
| Tempus | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $3.06B | Series G-5 | 4/30/2024 | $200M | $8.89B | $57.31 | Softbank | |||||
| OpenEvidence | Healthcare Healthcare Software | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | $250.33K | -- | 1 | -- | Not available | -- | -- | $893.23M | Series D-2 | 4/14/2026 | $192.5M | $12.19B | $487.38 | Undisclosed Investors | |||||
| Generate Biomedicines | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $812.92M | Series C | 1/21/2025 | $399.4M | $2.22B | $11.85 | Amgen, Nvidia, MAPS Capital, Pictet Alternative Advisors, Flagship Pioneering, Abu Dhabi Investment Authority, Fidelity, T. Rowe Price, ARCH Venture Partners, March Capital, Alaska Permanent Fund, Altitude Life Science Ventures, Novartis | |||||
| Cresilon | Healthcare Medical Devices | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | $102.50K | -- | 1 | -- | Not available | -- | -- | $126.97M | Series A-5 | 4/11/2025 | $41.25M | $338.51M | $2.04 | Undisclosed Investors | |||||
| Isomorphic Labs | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | $2.21M | -- | 3 | -- | Not available | -- | -- | -- | Not available | -- | -- | -- | -- | -- | |||||
| Devoted Health | Healthcare Healthcare Providers & Services | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | $281.91K | -- | 1 | Not available | -- | -- | $2.63B | Series F-Prime | 1/30/2026 | $317M | $16.27B | $67.50 | The Space Between, Centricus, GV, VZVC, Morgan Health, Franklin Venture Partners, VanEck, MIG Private Equity, Cox Enterprises, Premji Invest, The Private Shares Fund, NextView Ventures, Highbury, Emerson Collective, Andreessen Horowitz, BRONZE, Stardust Equity, General Catalyst, Frist Cressey Ventures, Fearless Ventures | |||||
| ZocDoc | Healthcare Digital Health | Low | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | $5.00 | +0.00% | -21.01% | $1.15B | Series D-2 | 2/11/2021 | $100M | $2.62B | $29.29 | Francisco Partners | |||||
| Apnimed | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | $200.00K | -- | 1 | -- | Not available | -- | -- | $249.52M | Series D-1 | 3/11/2026 | $25M | $428.39M | $9.66 | Undisclosed Investors | |||||
| Cytonics | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | -- | Not available | -- | -- | -- | -- | -- | |||||
| Dandy | Healthcare Healthcare Providers & Services | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $6.96M | Series Seed-1 | 11/14/2019 | $2.63M | $10.41M | $0.51 | The MBA Fund, Indicator Ventures, RiverPark Ventures, Human Capital | |||||
| Freenome | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $1.35B | Series F | 2/15/2024 | $263.96M | $2.05B | $7.40 | Roche, Andreessen Horowitz, BrightEdge Ventures, ARK Investments, ArrowMark Partners, Artis Ventures, Bain Capital, Cormorant Capital, DCVC, Eventide Asset Management LLC, Intermountain Ventures, Perceptive Advisors, Polaris Partners, Pura Vida Investments, Quest Diagnostics, RA Capital Management, Sands Capital, Section 32, Squarepoint Capital, T. Rowe Price Associates | |||||
| Collective Health | Healthcare Healthcare Providers & Services | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | $0.18 | +0.00% | -10.00% | $713.28M | Series F | 5/4/2021 | $280M | $1.53B | $0.75 | HCSC, DFJ Growth, Founders Fund, G Squared, Maverick Ventures, NEA, PFM Health Sciences, SoftBank, Sun Life Financial | |||||
| Rad AI | Healthcare Healthcare Software | Low | $xx.xx | $xx.xx | $xx.xx | xx% | -- | $141.00K | -- | 1 | Not available | -- | -- | $163.36M | Series C | 5/20/2025 | $80.9M | $527.53M | $22.51 | Transformation Capital, Khosla Ventures, World Innovation Lab, UP2398, Kickstart, OCV Partners, Cone Health, Advocate Health, Memorial Hermann Health System, Corewell Health, Atlantic Health System | |||||
| Xaira Therapeutics | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $1B | Series A | 4/23/2024 | $500M | $2.65B | $2.50 | ARCH Venture Partners, Foresite Capital, F-Prime, NEA, Sequoia Capital, Lux Capital, Lightspeed Venture Partners, Menlo Ventures, Two Sigma Ventures, Parker Institute for Cancer Immunotherapy, Byers Capital, Rsquared, SV Angel, AIM13, Breyer Capital, Deviation Capital, Foresite Labs, JSL Health Capital, Longwood Fund, Sahsen Ventures, WRF Capital | |||||
| ADARx Pharmaceuticals | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $505M | Series C | 8/9/2023 | $200M | $827.77M | $8.32 | Bain Capital Life Sciences, TCGX, Blackrock, Commodore Capital, Cormorant Asset Management, HBM Healthcare Investments, Invus, Marshall Wace, Redmile Group, T. Rowe Price Associates, Venrock Healthcare Capital Partners, Vivo Capital, Ascenta Capital, Lilly Asia Ventures, OrbiMed Advisors, SR One Capital Management | |||||
| Innovaccer | Healthcare Healthcare Software | Low | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | $2.62 | -14.10% | -20.36% | $653.62M | Series F-1 | 1/9/2025 | $153.04M | $3.45B | $7.39 | B Capital Group, Banner Health, Danaher Ventures, Generation IM, Kaiser Permanente, M12 | |||||
| Spring Health | Healthcare Digital Health | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $570.61M | Series D Aegis | 4/30/2026 | $130M | $3.52B | $69.22 | Undisclosed Investors | |||||
PLEASE READ THESE IMPORTANT LEGAL NOTICES & DISCLOSURES
Forge Price™ is a custom data-point calculated and disseminated by Forge Data LLC (“Forge Data”) and is a mark of Forge Data. Forge Price may rely on a very limited number of inputs in its calculation. Forge Price is prepared and disseminated solely for informational purposes. Redistribution is permitted solely with Forge’s written consent. While Forge has obtained information from sources it believes to be reliable, Forge does not perform an audit or undertake any duty of due diligence or independent verification of any information it receives. Forge does not guarantee the accuracy, completeness, timeliness, or availability of Forge Price, and are not responsible for any errors or omissions, regardless of the cause, or any results obtained from the use of Forge Price. Forge Price is derived from secondary activity on the Forge platform and other private market trading platforms, and other publicly-available datapoints collected by Forge. Forge Price is not intended to, and does not necessarily, represent the market price of any securities (I.e., the price at which you could buy or sell such securities). Neither reference to company names, nor calculation of Forge Price for a specific company, implies any affiliation between Forge and that company, any endorsement or sponsorship by Forge of any company or vice versa, or any partnership, joint venture or other commercial relationship between Forge and any company. Rights with respect to any company marks referred to herein are owned by the company. The dollar-figure and percentage displayed indicates the per share change in dollar amount and percentage since the most recent Forge Price change. Percentages are rounded to the nearest whole number.
The dollar-figure and percentage displayed indicates the per share change in dollar amount and percentage since the most recent Forge Price change. Percentages are rounded to the nearest whole number.
Post-Money Valuation (valuation) represents the estimated valuation based on company-submitted Certificates of Incorporations (COIs).
Market activity indicates the level of activity for a company based on recent IOIs, secondary transactions, and pending transactions.
Sector and subsector descriptions focus primarily on the types of companies within the respective sectors and subsectors that are typically available through Forge Markets. Any sector or subsector as a whole may include companies that participate in business lines in other sectors or subsectors. Companies are classified into sectors and subsectors according to the problem(s) they seek to solve rather than the method by which the solution is delivered.